Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
06/10/2026 24:01
BRIEF-Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA Oct 6 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX:
FDA TYPE C MEETING AFFIRMS ONGOING HEALEY ALS PLATFORM TRIAL AS POTENTIALLY REGISTRATIONAL
Further company coverage: NUZ.AX
((Reuters.Briefs@thomsonreuters.com))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon jumps on potential for neurodegenerative drug approval
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility